Waters & Kraus, LLP
Nationally defending mesothelioma victims against corporate greed.
Size of Organization: 42
Year Established: 1995Web Site: http://www.waterskraus.com
Toll Free: 800-226-9880
|Profile Visibility |
#200 in weekly profile views out of 281,287 total law firms Overall
Waters & Kraus, LLP is a mid-sized plaintiffs' firm with a successful national practice, as well as international experience. Our attorneys focus on toxic tort litigation (asbestos/mesothelioma), consumer product liability, as well as qui tam (whistleblower) and commercial litigation. With offices in Texas, California and Maryland, Waters & Kraus, LLP has litigated cases in jurisdictions across the United States on behalf of individuals from all 50 states, as well as foreign governments. To learn more about the firm and our practice, please go to www.waterskraus.com.
Martindale-Hubbell has augmented a firm's provided information with third-party sourced data to present a more comprehensive overview of the firm's expertise:
U.S. Federal Litigation Activity
Highest number of cases by Waters & Kraus, LLP:
Toxic Torts (52 cases in past two years)
Peer Review Ratings
Total number of Peer Review Rated lawyers of Waters & Kraus, LLP:
Documents by Waters & Kraus, LLP on Martindale.com
F.B.I. Investigates Power Morcellator Injuries
June 25, 2015
June 22, 2015 - The Federal Bureau of Investigation (F.B.I.) reportedly has launched an investigation into whether laws were broken by medical device manufacturers of the power morcellator device. Used in gynecologic surgery to perform hysterectomies and remove fibroid tumors, the power morcellator...
Method Discovered to Remove Benzene from Gasoline
June 24, 2015
Benzene exposure is a particular concern for those who work around gasoline and crude oil, both of which contain the dangerous substance. In fact, the U.S. Energy Information Administration estimates that Americans used 137 billion gallons of gasoline last year.
Standard Chemotherapy Regimen for Pleural Mesothelioma May Add Bevacizumab
Peter A. Kraus,Troyce G. Wolf, June 24, 2015
Malignant pleural mesothelioma may soon be getting a new standard of care. Bevacizumab may be added to the current standard chemotherapy regimen of pemetrexed and cisplatin. According to Dr. Gerald Zalcman, who recently presented a paper at the 2015 American Society of Clinical Oncology (ASCO)...